Faria-Costa Gabriel, Charrua Ana, Martins-Silva Carlos, Leite-Moreira Adelino, Antunes-Lopes Tiago
Department of Urology, Local Health Unit of Matosinhos, Matosinhos, Portugal; Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal; Cardiovascular Research and Development Center, Faculty of Medicine, University of Porto, Porto, Portugal.
Department of Biomedicine-Unit of Experimental Biology, Faculty of Medicine of University of Porto, Porto, Portugal; Institute of Investigation and Innovation in Health, University of Porto, Porto, Portugal; Department of Urology, University Hospital Center São João, Porto, Portugal.
Eur Urol Focus. 2022 Nov;8(6):1783-1786. doi: 10.1016/j.euf.2022.04.016. Epub 2022 May 20.
The heart and bladder share physiological biomechanical determinants of contraction. Heart failure (HF) and myogenic underactive bladder (mUAB) also share similarities in their pathophysiology. In both cases there is muscle injury that is directly linked to disease stage. In the final stage, both myocardium and detrusor show marked fibrosis and lower contractility. While HF has an established pharmacological treatment, there are still no effective drugs for mUAB. This mini-review explores the similarities between HF and mUAB and suggests that, as in HF, SGLT2 inhibitors may also have a beneficial role in mUAB. PATIENT SUMMARY: To date, there is no treatment for underactive bladder caused by problems with the bladder muscle (mUAB). We review similarities between this condition and heart failure and hypothesize that a recent drug class with striking results in heart failure might also have a beneficial role in mUAB.
心脏和膀胱在收缩的生理生物力学决定因素方面存在共性。心力衰竭（HF）和肌源性膀胱活动低下（mUAB）在病理生理学上也有相似之处。在这两种情况下，都存在与疾病阶段直接相关的肌肉损伤。在终末期，心肌和逼尿肌均表现出明显的纤维化和较低的收缩力。虽然HF已有既定的药物治疗方法，但mUAB仍然没有有效的药物。本综述探讨了HF和mUAB之间的相似性，并表明，与HF一样，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂可能对mUAB也有有益作用。患者总结：迄今为止，对于由膀胱肌肉问题导致的膀胱活动低下（mUAB）尚无治疗方法。我们回顾了这种情况与心力衰竭之间的相似性，并推测最近一类在心力衰竭治疗中取得显著效果的药物可能对mUAB也有有益作用。
